PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma.

Author: Min LUO ¹ ; Yuhui XIA ¹ ; Fang WANG ¹ ; Hong ZHANG ¹ ; Danting SU ¹ ; Chaoyue SU ¹ ; Chuan YANG ¹ ; Shaocong WU ¹ ; Sainan AN ¹ ; Suxia LIN ¹ ; Liwu FU ¹
Author Information

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Publication Type:Journal Article
Keywords: Combination therapy; ERK1/2; Immunotherapy; NSCLC; PD-1; PD-L1; PD0325901; Targeted therapy
From: Acta Pharmaceutica Sinica B 2021;11(10):3120-3133
CountryChina
Language:English
Abstract: ERK pathway regulated the programmed death ligand-1 (PD-L1) expression which was linked to the response of programmed death-1 (PD-1)/PD-L1 blockade therapy. So it is deducible that ERK inhibitor could enhance the efficacy of PD-1 inhibitor in cancer immunotherapy. In this study, PD0325901, an oral potent ERK inhibitor, strongly enhanced the efficacy of PD-1 antibody